Literature DB >> 9454711

Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide.

S C Hsu1, D Chargelegue, M W Steward.   

Abstract

In the work described here, the effect of intranasal immunization of BALB/c mice with synthetic chimeric peptides consisting of a cytotoxic T-cell epitope (amino acids 81-95) from the M2 protein of respiratory syncytial virus (RSV) and a fusion peptide (amino acids 113-131) from the F1 protein of measles virus on response to challenge with RSV has been assessed. Three intranasal immunizations with the chimeric peptides without adjuvant induce peptide- and RSV-specific cytotoxic T-cell responses (CTL) at 1 or 3 weeks after the third immunization. The CTL responses significantly declined at 6 weeks after immunization. Furthermore, viral load in the lungs following challenge with RSV was significantly reduced in mice immunized with the F/M2:81-95 chimeric peptide compared to control animals at 1 or 3 weeks after immunization and no reduction of RSV titers was detectable 6 weeks after immunization. The CTL activity induced by F/M2:81-95 was therefore short-lived (less than 6 weeks) but was significantly correlated with the reduction in viral load in the lungs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454711     DOI: 10.1006/viro.1997.8923

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Authors:  Ruihong Zeng; Huixian Zhang; Yan Hai; Yuxiu Cui; Lin Wei; Na Li; Jianxun Liu; Caixia Li; Ying Liu
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus.

Authors:  Nicholas W Lukacs; Martin L Moore; Brian D Rudd; Aaron A Berlin; Robert D Collins; Sandra J Olson; Samuel B Ho; R Stokes Peebles
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.

Authors:  Na Li; Ling Zhang; Boyang Zheng; Wenjian Li; Jianxun Liu; Huixian Zhang; Ruihong Zeng
Journal:  Hum Vaccin Immunother       Date:  2019-04-29       Impact factor: 3.452

4.  Steric recognition of T-cell receptor contact residues is required to map mutant epitopes by immunoinformatical programmes.

Authors:  Shiou-Chih Hsu; Chih-Peng Chang; Chao-Yuan Tsai; Shih-Hung Hsieh; Betty A Wu-Hsieh; Yu-Shu Lo; Jinn-Moon Yang
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

5.  A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.

Authors:  D Chargelegue; O E Obeid; S C Hsu; M D Shaw; A N Denbury; G Taylor; M W Steward
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus.

Authors:  Yeong-Min Jo; Jungwoo Kim; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2019-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.